Recruiting PHASE1 INTERVENTIONAL 4-arm NCT06589596

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors

Sponsor: BeOne Medicines

Conditions Advanced Solid Tumor

Interventions BG-89894 BGB-58067 Standard of Care Therapy

Updated 16 times since 2024 Last updated: Mar 3, 2026 Started: Oct 11, 2024 Primary completion: Jan 31, 2029 Completion: Jan 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumor and is currently actively recruiting participants. BeOne Medicines leads this study, which shows 16 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

16 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE1
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1

▶ Show 11 earlier versions

Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE1
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE1
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE1
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeOne Medicines

Data source: BeOne Medicines

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Beijing, China , Blacktown, Australia , Bordeaux, France , Boston, United States , Celebration, United States , Changchun, China , Chengdu, China , Chongqing, China , Clayton, Australia and 37 more locations